USPTO Examiner FALKOWITZ ANNA R - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17135006PIGMENT MIXTUREDecember 2020December 2024Abandon4701NoNo
17123625BIOACTIVE WOUND DRESSINGDecember 2020February 2023Abandon2620NoNo
17120007SELF-EMULSIFYING NANO-EMULSIONSDecember 2020February 2024Abandon3840NoNo
17118509NANOSCALE COATINGS FOR ENCAPSULATION OF BIOLOGICAL ENTITIESDecember 2020February 2023Allow2600YesNo
17081445USE OF UV RESISTANT ACTIVE MATERIALS ON HAIROctober 2020March 2023Allow2900NoNo
17066149POROUS CARBON MATERIAL COMPOSITES AND THEIR PRODUCTION PROCESS, ADSORBENTS, COSMETICS, PURIFICATION AGENTS, AND COMPOSITE PHOTOCATALYST MATERIALSOctober 2020March 2023Allow2910NoNo
17024486MTORC MODULATORS AND USES THEREOFSeptember 2020September 2021Allow1221YesNo
16981786ANTIBACTERIAL ANTIFUNGAL FIBER STRUCTURESeptember 2020August 2024Abandon4720YesNo
16979290A STABLE AGROCHEMICAL COMPOSITIONSeptember 2020August 2024Abandon4720NoNo
15733574Polyamine Prodrugs And Polyamine Prodrug FormulationsSeptember 2020June 2024Abandon4601NoNo
16991628BIODEGRADABLE SUPPORTING DEVICEAugust 2020November 2023Allow3930NoNo
16935027OCULAR DEVICE DELIVERY METHODS AND SYSTEMSJuly 2020August 2021Allow1321YesNo
16920789COMPOSITIONS CONTAINING LATEX PARTICLES AND INORGANIC METAL OXIDESJuly 2020October 2021Abandon1520NoNo
16918704CONTROLLED-RELEASE TABLETS, METHOD OF MAKING, AND METHOD OF USE THEREOFJuly 2020February 2024Allow4411YesNo
16958659Heterocyclic Amides as Kinase InhibitorsJune 2020July 2023Allow3700NoNo
16955847COSMETIC COMPOSITION COMPRISING SILICONE MATERIALSJune 2020March 2024Allow4511NoNo
16904097BIOCOMPATIBLE FIBER TEXTILES FOR IMPLANTATIONJune 2020October 2021Allow1611NoNo
16898309COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOFJune 2020July 2022Allow2610NoNo
16893597BIODEGRADABLE SUPPORTING DEVICE WITH A RADIO-OPAQUE MARKERJune 2020August 2021Abandon1411NoNo
16767703HYDROPHOBIC POLYMERS AS OIL RHEOLOGY MODIFIERS FOR AGROCHEMICAL FORMULATIONSMay 2020February 2024Allow4530YesNo
16766840METHOD FOR PRODUCING POLYETHERESTER POLYOLSMay 2020December 2023Abandon4201NoNo
16880634METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATIONMay 2020November 2023Abandon4251YesNo
16761889ANTIMICROBIAL DRESSINGMay 2020December 2023Abandon4330NoNo
16847000SUPERPOROUS HYDROGELS, METHODS OF MAKING THE SAME, AND ARTICLES INCORPORATING THE SAMEApril 2020March 2024Abandon4761YesNo
16844222ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES, METHODS OF MAKING ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES, AND METHODS OF USING ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIESApril 2020January 2021Allow910YesNo
16843376UNIVERSAL CARDIOPLEGIC SOLUTION (VARIANTS)April 2020December 2020Allow920YesNo
16754367HYDROGEL BEADSApril 2020February 2022Allow2211YesNo
16826577EMBOLIC MICROSPHERES AND METHODSMarch 2020November 2023Abandon4421YesYes
16626997FILM-FORMING AGENT FOR COSMETICS AND COSMETICS CONTAINING SAMEMarch 2020December 2021Abandon2420NoNo
16648827POWDERY COMPOSITIONMarch 2020June 2022Abandon2731YesNo
16817299PROGRAMMABLE LIQUID, GEL AND BIOHYBRID COMPARTMENTS AND METHODS OF USEMarch 2020October 2022Allow3141NoNo
16812700COMPOSITIONS AND METHODS FOR RESHAPING KERATIN-RICH SUBSTRATES AND FORMING ADHERENT FLEXIBLE FILMSMarch 2020January 2022Allow2221YesNo
16642993NUCLEIC ACID-LOADED UNIT POLYION COMPLEXFebruary 2020February 2022Allow2330YesNo
16803494TISSUE CUFFFebruary 2020April 2024Abandon4911NoNo
16800461REMOVABLE FILM FORMING GEL COMPOSITIONS AND METHODS FOR THEIR APPLICATIONFebruary 2020January 2021Abandon1110NoNo
16640364ADHESION PREVENTION MATERIALFebruary 2020March 2024Abandon4940NoNo
16794367TWO-STEP REACTIVE LIP SYSTEMFebruary 2020March 2023Abandon3750NoNo
16638857ANTIMICROBIAL/ANTIVIRAL COMPOSITIONFebruary 2020April 2024Abandon5052YesNo
16638897IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDSFebruary 2020March 2022Allow2521YesNo
16636127Adhesion Materials and Methods of ManufactureFebruary 2020December 2024Abandon5821NoNo
16777950NEGATIVE PRESSURE WOUND DRESSING AND NEGATIVE PRESSURE WOUND TREATMENT DEVICEJanuary 2020October 2023Abandon4401NoNo
16633951WOUND DRESSING COMPRISING HYALURONIC ACID-CALCIUM AND POLYLYSINE AND MANUFACTURING METHOD THEREFORJanuary 2020April 2024Abandon5121NoNo
16633507ELECTROSPUN NANOFIBERS AND MEMBRANEJanuary 2020June 2023Allow4111YesNo
16741558UV-PROTECTIVE COMPOSITIONSJanuary 2020December 2020Abandon1140YesNo
16627094POLYMER FOR DELIVERY OF BIOLOGICALLY ACTIVE MATERIALSDecember 2019June 2022Allow3010YesNo
16625046TISSUE REPAIR LAMINATESDecember 2019October 2023Allow4660YesNo
16622056PROCESS FOR PREPARING ORGANOPOLYSILOANE GELSDecember 2019January 2023Allow3801YesNo
16621011ANTIMICROBIAL POLYMER COMPOSITIONDecember 2019July 2023Allow4361YesNo
16619633HIGH-THROUGHPUT SYNTHESIS OF BIOMOLECULE-POLYMER CONJUGATESDecember 2019December 2024Abandon6041YesNo
16704993MULTIFUNCTIONAL HYBRID AEROGELSDecember 2019September 2023Abandon4611NoNo
16703086SELF-EXPANDABLE STENT AND METHOD OF PRODUCING THE SAMEDecember 2019July 2024Abandon5551NoNo
16700130NON-IONIC COACERVATES FOR DRY, HUMID AND WET ADHESIONDecember 2019February 2021Allow1520NoNo
16699138COMPOSITE FIBERNovember 2019May 2023Abandon4121NoNo
16616270USE OF SPECIFIC POLYMERS TO BRING ABOUT AN ANTI-POLLUTION EFFECTNovember 2019November 2021Abandon2311NoNo
16616203ALKYLENE OXIDE DERIVATIVES, WETTING AGENT, SOLUBILIZING AGENT, AND SOLUBILIZING COMPOSITIONNovember 2019February 2024Abandon5121NoNo
16616437Multifunctional Treatment And Diagnostic Compositions And MethodsNovember 2019March 2022Allow2731YesNo
16690571BIOINERT BODYNovember 2019December 2022Abandon3710NoNo
16687789POLYMERIC SYSTEMS AND USES THEREOF IN THERANOSTIC APPLICATIONSNovember 2019November 2023Abandon4821NoNo
16614307LONG-CIRCULATING ZWITTERIONIC POLYPLEXES FOR siRNA DELIVERYNovember 2019June 2023Abandon4340NoYes
16683306DISPOSABLE MEDICAL DEVICE FOR MEDICATION OF SKIN LESIONS AND METHOD THEREFORENovember 2019May 2024Abandon5431NoNo
16681085MEDICAL IMPLANT WITH POROUS PLASMA POLYMER COATINGNovember 2019August 2023Abandon4521NoNo
16611787DYE COMPOSITION BASED ON COPOLYMERS DERIVED FROM THE POLYMERIZATION OF AT LEAST ONE CROTONIC ACID MONOMER OR CROTONIC ACID DERIVATIVE AND OF AT LEAST ONE VINYL ESTER MONOMER AND SILICONE, AND PROCESS FOR DYEING KERATIN FIBERS USING SAMENovember 2019December 2022Abandon3731YesYes
16675417METHOD FOR GENTLE, CHEMICAL HAIR TREATMENTNovember 2019August 2021Allow3010YesNo
16609544ENHANCED SOLUBILITY DRUG-CONTAINING FORMULATIONSOctober 2019January 2023Allow3921YesNo
16607180SEALING AGENT FOR GENITALSOctober 2019February 2022Abandon2810YesNo
16594878MICROCAPSULES AND METHODS OF USING THE SAMEOctober 2019August 2022Allow3511YesNo
16585484Biocompatible Polycaprolactone Fumarate FormulationsSeptember 2019June 2021Abandon2020NoNo
16498595REVERSE THERMAL GELS AND THEIR USE AS VASCULAR EMBOLIC REPAIR AGENTSSeptember 2019January 2023Allow4021YesNo
16541570POLYMER BEADAugust 2019September 2022Abandon3741YesNo
16515946NANOFIBER-HYDROGEL COMPOSITES FOR CELL AND TISSUE DELIVERYJuly 2019January 2023Allow4231YesYes
16508637RAPIDLY DISINTEGRATING ORAL DISSOLVABLE FILMJuly 2019January 2022Allow3140YesNo
16477417NONWOVEN MATERIAL FOR CLEANING AND SANITIZING SURFACESJuly 2019May 2023Abandon4620NoNo
16456023DUAL PHASE PRODUCTSJune 2019November 2022Allow4130YesNo
16473896Absorbable Iron-Based InstrumentJune 2019February 2023Allow4440YesNo
16473267STENT MADE OF A BIO-DEGRADABLE MAGNESIUM ALLOY WITH A MAGNESIUM FLUORIDE COATING AND AN ORGANIC COATINGJune 2019July 2023Allow4950YesNo
16444206METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATIONJune 2019February 2020Allow810NoNo
16445000WAX FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOFJune 2019November 2020Allow1720YesNo
16467627DENTAL COMPOSITIONJune 2019November 2023Allow5341NoNo
16466872Composition comprising polyurethane microcapsules comprising cinmethylinJune 2019July 2021Abandon2501NoNo
16463038SEED COATING COMPOSITIONMay 2019December 2021Allow3121YesNo
16419815BIODEGRADABLE SUPPORTING DEVICE WITH A RADIO-OPAQUE MARKERMay 2019January 2022Abandon3241NoNo
16412047METHOD FOR DELIVERING PHARMACEUTICAL NANOPARTICLES TO CANCER CELLSMay 2019March 2020Allow1010NoNo
16410665METHODS FOR ADVERSELY AFFECTING BIOFILMSMay 2019May 2021Abandon2440NoNo
16393597PHARMACEUTICAL COMPOSITION COMPRISING ELECTROHYDRODYNAMICALLY OBTAINED FIBRES, THE COMPOSITION HAVING IMPROVED RESIDENCE TIME ON THE APPLICATION SITEApril 2019November 2022Abandon4330YesYes
16344078USE OF CATIONIC POLYMER HAVING QUATERNARY AMMONIUM GROUPS FOR THE PROTECTION OF HAIR AGAINST UV DAMAGEApril 2019April 2023Abandon4731NoNo
16341726COLLAGEN AND COLLAGEN LIKE PEPTIDE BASED HYRDOGELS, CORNEAL IMPLANTS, FILLER GLUE AND USES THEREOFApril 2019April 2022Allow3621YesNo
16376552METHODS OF PRODUCING OPTIMIZED GENE-ACTIVATED MATERIALSApril 2019January 2024Allow5741YesYes
16339293SILICONE RESIN-LINEAR COPOLYMER AND RELATED METHODSApril 2019December 2021Abandon3321NoNo
16338330PHOSPHORYLATED TRI-BLOCK COPOLYMERS WITH ANTI-MICROBIAL PROPERTIESMarch 2019September 2022Allow4231NoNo
16338103COMPOSITIONS OF POLYMERIC NANOWIRES AND METHODS OF MAKING AND USING THEREOFMarch 2019November 2021Allow3130YesNo
16365591POLYURETHANE/UREA COMPOSITIONSMarch 2019January 2020Allow1010NoNo
16334562COPOLYMER COMPOSITION FOR COATING AND ADHESIVE APPLICATIONSMarch 2019January 2023Abandon4621NoNo
16334584COPOLYMER COMPOSITION FOR PERSONAL CAREMarch 2019April 2022Abandon3711NoNo
16289165METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATIONFebruary 2019June 2019Allow310YesNo
16329534Coating of Nanoparticle Surfaces with Cyclopeptides for Improving Delivery of Agents Via the Oral RouteFebruary 2019April 2021Abandon2620NoNo
16327472COMPOSITION FOR ARTICULAR CAVITY INJECTION COMPRISING NUCLEIC ACID AND CHITOSANFebruary 2019November 2021Allow3220YesNo
16326606NON-VIRAL DELIVERY AGENTS FROM POLYELECTROLYTES BASED ON CYCLOPROPENIUM IONS, THEIR SYNTHESES, AND USES THEREOFFebruary 2019April 2022Abandon3701NoNo
16274123COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOFFebruary 2019March 2020Allow1320YesNo
16270206METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATIONFebruary 2019May 2019Allow410YesNo
16323477COMPOSITION FOR THE TREATMENT OF A FUNGAL INFECTIONFebruary 2019September 2023Abandon5521YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FALKOWITZ, ANNA R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
16
Examiner Affirmed
7
(43.8%)
Examiner Reversed
9
(56.2%)
Reversal Percentile
81.6%
Higher than average

What This Means

With a 56.2% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
63
Allowed After Appeal Filing
24
(38.1%)
Not Allowed After Appeal Filing
39
(61.9%)
Filing Benefit Percentile
63.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 38.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner FALKOWITZ, ANNA R - Prosecution Strategy Guide

Executive Summary

Examiner FALKOWITZ, ANNA R works in Art Unit 1617 and has examined 633 patent applications in our dataset. With an allowance rate of 49.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner FALKOWITZ, ANNA R's allowance rate of 49.8% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FALKOWITZ, ANNA R receive 2.50 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FALKOWITZ, ANNA R is 33 months. This places the examiner in the 45% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +51.4% benefit to allowance rate for applications examined by FALKOWITZ, ANNA R. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.1% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.6% of cases where such amendments are filed. This entry rate is in the 27% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 26.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 70.4% of appeals filed. This is in the 57% percentile among all examiners. Of these withdrawals, 42.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 79.6% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 62% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.